Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

Wachovia Downgrades Nabi Biopharmaceuticals


Wachovia downgraded Nabi Biopharmaceuticals (NABI) to market perform from outperform.

Analyst Martin Auster says he is downgrading Nabi on less favorable risk/reward ahead of Phase III StaphVAX trial in late third quarter to early fourth quarter. Over the next six to 12 months, he thinks Nabi stock is susceptible to trading as low as $5-$6, and as high as the low-$20s, with the outcome of Phase III StaphVAX trial being the pivotal swing factor.

Auster doesn't see a risk-reward profile that would compel him to advocate putting fresh money into Nabi at current near-$16 price. Otherwise, he retains his opinion that the StaphVAX Phase III trial is probable to succeed, though he believes moderate clinical risk exists.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus